Начало › Рак на белия дроб с недребноклетъчен тип › Небраска › Omaha
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Omaha, NE
24 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Omaha (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Nebraska Medicine-Village Pointe, Omaha
- и още 3
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Oncology Hematology West PC, Omaha
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Набиране на участнициФаза 1
- Exelixis Clinical Site #2, Omaha
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University Of Nebraska Medical Center, Omaha
- и още 1
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Набиране на участнициФаза 3
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Methodist, Omaha
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan, Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Набиране на участнициФаза 3
- Research Site, Omaha
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Research Site, Omaha
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Набиране на участнициФаза 2/3
- Local Institution - 007-590A, Omaha
- Local Institution - 007-590B, Omaha
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
- и още 1
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Набиране на участнициФаза 1
- Nebraska Cancer Specialists, Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Набиране на участнициФаза 1/2
- Nebraska Cancer Specialists, Omaha
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- University of Nebraska Medical Center, Omaha
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 3
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · на 9 мили
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 2
- University of Nebraska Medical Center, Omaha
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Набиране на участнициФаза 1
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Набиране на участнициФаза 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, Omaha
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Набиране на участнициФаза 2
- University of Nebraska Medical Center, Omaha
Repositioning Immunotherapy in VetArans With Lung Cancer
Набиране на участнициФаза 2
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Nebraska Cancer Specialists, Omaha
GEMINI-NSCLC: NSCLC Biomarker Study
Набиране на участнициНаблюдателно проучване
- Nebraska Cancer Specialists, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Omaha
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Набиране на участнициФаза 1
- Nebraska Cancer Specialists, Omaha
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY120 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH56 проучвания
- Washington, DC55 проучвания
Други проучвания в Omaha
- Рак на простатата27 проучвания
- Рак на гърдата22 проучвания
- Колоректален рак18 проучвания
- Рак (всички видове)18 проучвания
- Множествен миелом16 проучвания
- Нон-Ходжкинов лимфом14 проучвания
- Рак на яйчниците14 проучвания
- Рак на панкреаса14 проучвания
- Плоскоклетъчен карцином на главата и шията13 проучвания
- Сърдечна недостатъчност13 проучвания
- Метастатичен рак13 проучвания
- Рак на бъбрека (бъбречноклетъчен карцином)12 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.